Edwards Lifesciences Corporation $EW Stock Position Cut by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 13.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 531,398 shares of the medical research company’s stock after selling 79,593 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Edwards Lifesciences were worth $45,870,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in EW. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $1,274,082,000. Bank of America Corp DE acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $605,397,000. Deutsche Bank AG acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $516,552,000. Finally, Legal & General Group Plc bought a new position in Edwards Lifesciences in the 2nd quarter valued at approximately $389,089,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,428,912.10. This trade represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 5,045 shares of company stock worth $451,596. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EW. BTIG Research restated a “buy” rating and issued a $110.00 target price on shares of Edwards Lifesciences in a research report on Friday, September 11th. Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Raymond James Financial boosted their price objective on Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $90.15 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 52 week low of $74.66 and a 52 week high of $96.29. The firm has a market cap of $51.91 billion, a PE ratio of 51.81, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87. The firm’s fifty day moving average is $88.10 and its 200-day moving average is $86.60.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.